Celgene says Revlimid delays multiple myeloma

	Tweet

Celgene Corp. on Monday said initial results from two pivotal-stage trials show that its blood cancer drug Revlimid (lenalidomide) in combination with chemotherapy significantly delays progression of multiple myeloma in relapsed patients.

At the time of the interim analysis, the median time to progression for patients in the U.S. trial was at least 15 months and for the international trial more than 11 months. Patients treated with only chemotherapy in both trials had a median time to progression of five months, the company said.

"In multiple myeloma patients with resistant disease, Revlimid plus dexamethasone more than doubled the response rate compared with desamethasone alone, confirming that Revlimid has the potential to be an important new agent for multiple myeloma,” Dr. Donna Weber, associate professor, lymphoma/myeloma at the University of Texas MD Anderson Cancer Center, said in a statement.

Celegene said it plans to use data from both trials as the basis for marketing applications to the U.S. Food and Drug Administration and regulatory agencies in other countries.

The studies were presented at the International Multiple Myeloma Workshop in Sydney, Australia. 

RELATED STORIES:
Disease diagnosis in just 15 minutes   Cancer raises blood clot risk by sevenfold   Environmental Exposures May Damage DNA in as Few as Three Days   Thyroid Nodules in Children Pose Greater Risk of Malignancy   Racial gap seen in genetic testing and counseling   Diabetes and cancer: A shared biological basis   Endometrial cancer worse in African-American women   High tech twist to ancient drug kills cancer   Evidence ties smoking to throat, stomach cancer   Vitamin E May Harm Patients With Head, Neck Cancers   Birth size linked to some adult cancers   Smoking may worsen pain for cancer patients

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]